Back to User profile » Dr Raymond Rosen
Paper published by Dr Raymond Rosen:
Original Research
![Noteworthy comment: This paper is noteworthy because it describes a new tool to assess patients’ perspectives on a serious, often distressing aspect of a chronic mental illness—ie, cognitive impairment associated with schizophrenia. As recommended by the FDA’s guidance on patient-reported outcome (PRO) measures, the multistage development process utilized by the investigators incorporated quantitative and qualitative data from patients and providers. Given the importance to patients of receiving understandable information about their conditions, this new PRO measure may prove valuable in building a therapeutic alliance with patients with schizophrenia. Furthermore, following psychometric validation in an ongoing clinical trial, the measure could define key patient-oriented endpoints for future trials.](assets/img/article_icons/noteworthy.png)
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/rewwHVcpmts/1.jpg)
Welch LC, Trudeau JJ, Silverstein SM, Sand M, Henderson DC, Rosen RC
Patient Related Outcome Measures 2017, 8:71-81
Published Date: 8 June 2017